2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143585
    CDK9-IN-14
    		Inhibitor 99.91%
    CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC50 of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects.
    CDK9-IN-14
  • HY-RS02348
    CDK1 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK1 Human Pre-designed siRNA Set A
  • HY-400528
    CLK1-IN-4
    		Inhibitor 99.75%
    CLK1-IN-4 (Compound 79) is an inhibitor for CDC like kinase 1 (CLK-1) with IC50 of 1.5-2 μM.
    CLK1-IN-4
  • HY-111463
    CDK8-IN-3
    		Inhibitor 98.17%
    CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
    CDK8-IN-3
  • HY-RS02401
    CDK9 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK9 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK9 Human Pre-designed siRNA Set A
  • HY-N12625A
    (S)-(-)-O-Demethylbuchenavianine
    		Inhibitor
    (S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoidal alkaloids. (S)-(-)-O-Demethylbuchenavianine is a potent CDK inhibitor, with IC50 values of 0.03 and 0.05 μM for CDK1 and CDK5, respectively.
    (S)-(-)-O-Demethylbuchenavianine
  • HY-172245
    Zeltociclib
    		Inhibitor
    Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
    Zeltociclib
  • HY-12871C
    Atuveciclib S-Enantiomer
    		Inhibitor 99.38%
    Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, which inhibits CDK9/CycT1 with an IC50 of 16 nM.
    Atuveciclib S-Enantiomer
  • HY-101257A
    CDK7-IN-1
    		Inhibitor 98.91%
    CDK7-IN-1, an analog of YKL-5-124, is a cyclin-dependent kinase 7 (cdk7) inhibitor, with an IC50 of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215.
    CDK7-IN-1
  • HY-143430A
    (S)-LY3177833 hydrate
    		Inhibitor
    (S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity.
    (S)-LY3177833 hydrate
  • HY-13266
    BS-181
    		Inhibitor 98.10%
    BS-181 is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy.
    BS-181
  • HY-139011
    IV-361
    		Inhibitor 99.60%
    IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1).
    IV-361
  • HY-100023A
    LY3177833 monhydrate
    		Inhibitor 99.76%
    LY3177833 (Example 4) monhydrate is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 monhydrate is a senescence inducer.
    LY3177833 monhydrate
  • HY-114177A
    (S)-Ebvaciclib
    		Control 98.18%
    (S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).
    (S)-Ebvaciclib
  • HY-RS02356
    CDK12 Human Pre-designed siRNA Set A
    		Inhibitor

    CDK12 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDK12 Human Pre-designed siRNA Set A
  • HY-W011109
    CKI-7
    		Inhibitor 98.41%
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
    CKI-7
  • HY-168556
    YJ9069
    		Degrader
    YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC50 of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth. (Pink: CDK12/CDK13 degradation agent (HY-168658); Black: Linker (HY-W015967); Blue: ligand for E3 ligase (HY-103596)).
    YJ9069
  • HY-100035
    PT-262
    		Inhibitor 99.21%
    PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity.
    PT-262
  • HY-RS02309
    CDC7 Human Pre-designed siRNA Set A
    		Inhibitor

    CDC7 Human Pre-designed siRNA Set A contains three designed siRNAs for CDC7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CDC7 Human Pre-designed siRNA Set A
  • HY-171787
    PPA-037
    		Inhibitor
    PPA-037 is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12). PPA-037 induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 is promising for research of cancers.
    PPA-037
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.